Yara Sheeni

Ms. Yara Sheeni


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
ASAseel Saadi
Aseel Saadi
SSSereen Sandouka
Sereen Sandouka
Rhoda OloweRhoda Olowe
Rhoda Olowe
YSYara Sheeni
Yara Sheeni
Tawfeeq Shekh-AhmadTawfeeq Shekh-Ahmad
Tawfeeq Shekh-Ahmad
Background/Objectives: Acute seizure models are widely used in epilepsy research to investigate seizure mechanisms and evaluate antiseizure drug efficacy. Among these models, pentylenetetrazole (PTZ)-induced seizures provide a controlled and reproducible approach to study acute seizure dynamics. However, existing PTZ protocols often suffer from inconsistent seizure induction, high mortality rates, and limited translational relevance. Methods: In this study, we systematically evaluated different PTZ dosing regimens in adult Sprague-Dawley rats to establish an optimized acute seizure model that balances seizure induction efficiency with minimal lethality. Results: We tested multiple PTZ administration protocols, identifying a two-step regimen of 50 mg/kg followed by 30 mg/kg (30 min later) as the most effective strategy. This dosing approach reliably induced generalized tonic-clonic seizures in 94% of the animals while eliminating mortality. Seizures induced by this regimen were validated through electrocorticography (ECoG) recordings. The behavioral and ECoG assessments of seizures showed a strong agreement in the latency and duration (r = 0.97, p < 0.0001; r = 0.81, p < 0.05, respectively) with minimal bias in Bland–Altman analysis, confirming that both methods provide statistically comparable and interchangeable measures of seizure characteristics. Conclusions: Our findings highlight the robustness and reproducibility of this modified PTZ-induced acute seizure model, offering an improved preclinical platform for studying seizure pathophysiology and screening for novel therapeutic interventions.

7 October 2026 in Antioxidants
Verified
Journal Article
Open access
PDF file
YSYara Sheeni
Yara Sheeni
Prince Kumar SinghPrince Kumar Singh
Prince Kumar Singh
SHWETA MAURYASHWETA MAURYA
SHWETA MAURYA
SSSereen Sandouka
Sereen Sandouka
Tawfeeq Shekh-AhmadTawfeeq Shekh-Ahmad
Tawfeeq Shekh-Ahmad
We aimed to investigate the acute anticonvulsant and long-term antiepileptogenic effects of the synthetic triterpenoid CDDO-EA in complementary experimental models of epilepsy. CDDO-EA was evaluated in the pentylenetetrazol seizure model and a kainic acid-induced post-status epilepticus model. Acute seizure severity, latency to generalized seizures, oxidative stress and inflammatory markers, spontaneous recurrent seizures, and hippocampal neuronal survival were assessed. In the pentylenetetrazol model, CDDO-EA pretreatment reduced maximal seizure severity and prolonged the latency to stage V-VI seizures. These effects were associated with decreased inflammatory cytokine levels and malondialdehyde levels, alongside increased superoxide dismutase and catalase activities 24 h after pentylenetetrazol administration. In the post-status epilepticus model, two weeks of CDDO-EA treatment significantly delayed the onset of spontaneous recurrent seizures and produced sustained reductions in weekly seizure frequency and cumulative seizure burden. Histological analysis demonstrated greater neuronal preservation in the hippocampal CA1 and CA3 regions of CDDO-EA-treated animals compared with vehicle controls. CDDO-EA exerts both anticonvulsant and disease-modifying effects by attenuating seizure severity, restoring redox-inflammatory homeostasis, preserving hippocampal neurons, and suppressing epileptogenesis after status epilepticus, supporting its therapeutic potential as a novel strategy for epilepsy.